Fotemustine

Search with Google Search with Bing

Information
Drug Name
Fotemustine
Description
Entry(CIViC)
CIViC
[No Data.]
Annotation
Description Associated Genes Associated Variants Sensitivity Supported Source Links
MGMT-transfected cells were 7 to 9 times less sens... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
The O(6)-methylguanine-DNA methyltransferase (MGMT... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
Melanoma lines expressing p53 wild-type were more ... TP53 TP53 WILD_TYPE Resitance or Non-Reponse true MMMP detail
O(6)-methylguanine DNA-methyltransferase (MGMT) ov... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
These data show that Rev3L contributes to temozolo... REV3L REV3L UNDEREXPRESSION Sensitivity true MMMP detail
Uveal melanoma. These results do not support MGMT ... MGMT MGMT METHYLATION Resitance or Non-Reponse true MMMP detail
MGMT gene (not promoter) demethylation by 5-AZA in... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Acquired resistance to fotemustine was alleviated ... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
ROS inhibits fotemustine effect ROS1 ROS1 UNDEREXPRESSION Sensitivity true MMMP detail
MGMT inactivation by O(6)-benzylguanine sensitized... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Uveal melanoma. These results do not support MGMT ... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
Coincubation of melanoma cells with O6-benzylguani... MGMT MGMT UNDEREXPRESSION Sensitivity true MMMP detail
Uveal melanoma. These results do not support MGMT ... MGMT MGMT METHYLATION Resitance or Non-Reponse true MMMP detail
Strong synergistic proapoptotic effect of the Bcl-... BCL2 BCL2 UNDEREXPRESSION Sensitivity true MMMP detail
Decreasing levels of p53 mRNA correlated with incr... TP53 TP53 EXPRESSION Sensitivity true MMMP detail
Decreased expression associated with resistance MLH1 MLH1 EXPRESSION Sensitivity true MMMP detail
Decreased expression associated with resistance MSH2 MSH2 EXPRESSION Sensitivity true MMMP detail
Increased expression associated with resistance MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
Short interfering RNA directed against the SLUG ge... SNAI2 SNAI2 UNDEREXPRESSION Sensitivity true MMMP detail
Determination of O6-methylguanine-DNA methyltransf... MGMT MGMT OVEREXPRESSION Resitance or Non-Reponse true MMMP detail
Compared with control cells, both MGMT mRNA and MG... MGMT MGMT EXPRESSION Resitance or Non-Reponse true MMMP detail
There was only an insignificant difference in the ... MGMT MGMT METHYLATION Resitance or Non-Reponse true MMMP detail
NCT ID Status Phase Summary Start date Completion date
NCT00560118 Completed Phase 2 Fotemustine in Treating Patients With Metastatic Melanoma August 2003
NCT01069627 Completed Phase 2 A Study of Avastin (Bevacizumab) in Combination With Fotemustine in Patients With Metastatic Melanoma December 2006 July 2009
NCT01359956 Completed Phase 3 Fotemustine and Dacarbazine Versus Dacarbazine +/- Alpha Interferon in Advanced Malignant Melanoma April 2002 February 2011
NCT01474239 Completed Phase 2 A Study of Avastin (Bevacizumab) And Fotemustine in Patients With Recurrent Glioblastoma November 2011 December 2013
NCT00110123 Terminated Phase 3 Intravenous or Hepatic Arterial Infusion of Fotemustine in Treating Patients With Unresectable Liver Metastases From Eye Melanoma January 2005
NCT02460068 Unknown status Phase 3 A Study of Fotemustine(FTM) Vs FTM and Ipilimumab (IPI) or IPI and Nivolumab in Melanoma Brain Metastasis December 2012 January 2020